Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC
Public ClinicalTrials.gov record NCT05059327. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive Therapy in Children, Adolescents, and Young Adults With Uncontrolled Seizures Associated With Tuberous Sclerosis Complex
Study identification
- NCT ID
- NCT05059327
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Noema Pharma AG
- Industry
- Enrollment
- 61 participants
Conditions and interventions
Conditions
Interventions
- Basimglurant with crossover to Placebo Drug
- Placebo with crossover to Basimglurant Drug
Drug
Eligibility (public fields only)
- Age range
- 5 Years to 30 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2, 2022
- Primary completion
- Feb 5, 2025
- Completion
- Apr 27, 2025
- Last update posted
- Jun 3, 2025
2022 – 2025
United States locations
- U.S. sites
- 9
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| David Geffen School of Medicine at UCLA (Site #: 101) | Los Angeles | California | 90095 | — |
| Kennedy Krieger Institute (Site #: 110) | Baltimore | Maryland | 21205 | — |
| Boston Children's Hospital (Site #: 102) | Boston | Massachusetts | 02115-5724 | — |
| William Beaumont Hospital - Royal Oak (Site #: 104) | Royal Oak | Michigan | 48073-6712 | — |
| Minnesota Epilepsy Group PA (Site #: 105) | Roseville | Minnesota | 55113-1306 | — |
| Boston Children's Health Physicians (BCHP) (Site #: 111) | Hawthorne | New York | 10532 | — |
| Duke Children's Hospital and Health Center (Site #: 106) | Durham | North Carolina | 27705-4699 | — |
| University Hospitals Cleveland Medical Center, Rainbow Babies and Childrens Hospital (Site #: 107) | Cleveland | Ohio | 44106-1716 | — |
| The University of Texas Medical School at Houston (Site #: 103) | Houston | Texas | 77030-3000 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05059327, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 3, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05059327 live on ClinicalTrials.gov.